Viking Therapeutics, Inc. 10-Q

Item 2. Unregistered Sales of Equi ty Securities and Use of Proceeds Issuer Purchases of Equity Securities During the three months ended June 30, 2023, we satisfied certain U.S. federal and state tax withholding obligations due upon the vesting of restricted stock unit awards by automatically withholding from the shares being issued in connection with such award a number of shares of our common stock with an aggregate fair market value on the date of vesting equal to the minimum tax withholding obligations. The following table sets forth information with respect to shares of our common stock withheld by us to satisfy certain tax withholding obligations during the quarter ended June 30, 2023: Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Maximum Number (or Approximate Dollar Value) of Shares that May Yet be Purchased Under the Plans or Programs April 1, 2023 – April 30, 2023 (307,781 ) (1) $ 17.57 — $ 47,556,793 (2) May 1, 2023 – May 31, 2023 — — — 47,556,793 (2) June 1, 2023 – June 30, 2023 — — — 47,556,793 (2) Total (307,781 ) $ 17.57 — $ 47,556,793 (1) Represents shares of our common stock withheld from employees for the payment of taxes. (2) On March 10, 2022, our board of directors authorized a new stock repurchase program effective March 18, 2022, whereby we may purchase up to $50.0 million in shares of our common stock over a period of up to two years (the “New Repurchase Program”). The New Repurchase Program may be carried out at the discretion of a committee of our board of directors through open market purchases, one or more Rule 10b5-1 trading plans, block trades and in privately negotiated transactions. We did not repurchase any shares of our common stock under the New Repurchase Program during the quarter ended June 30, 2023. Item 3. Defaults Upo n Senior Securities Not applicable. Item 4. Mine Saf ety Disclosures Not applicable.